
Terese Capizzi: End Medicare restrictions on Alzheimer’s treatments
Last year, Medicare issued an unprecedented policy that placed restrictions on monoclonal antibodies to require patients to be enrolled in either a randomized clinical trial or a prospective comparative study to receive the FDA-approved treatments.
























